Megan Othus

Research interests

Publications

• Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2211437

• Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

  Journal for ImmunoTherapy of Cancer · 2021 · https://doi.org/10.1136/jitc-2021-002990

• A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

  Clinical Cancer Research · 2020 · https://doi.org/10.1158/1078-0432.ccr-19-3356

• Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2015.66.2510

• Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis

  Haematologica · 2017 · https://doi.org/10.3324/haematol.2016.159343

• Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia

  Leukemia · 2016 · https://doi.org/10.1038/leu.2016.46

• US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL

  Blood Advances · 2016 · https://doi.org/10.1182/bloodadvances.2016001495

• Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission?

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2015.63.3826

• Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70281-5

• Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center

  Leukemia · 2014 · https://doi.org/10.1038/leu.2014.242

• Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients

  Blood · 2013 · https://doi.org/10.1182/blood-2012-10-462440

• Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson

  Leukemia · 2013 · https://doi.org/10.1038/leu.2013.176

• Cure Models as a Useful Statistical Tool for Analyzing Survival

  Clinical Cancer Research · 2012 · https://doi.org/10.1158/1078-0432.ccr-11-2859

• Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2011.35.7525

• Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience

  Blood · 2010 · https://doi.org/10.1182/blood-2010-02-270330

• Parental Decision Making about the HPV Vaccine

  Cancer Epidemiology Biomarkers & Prevention · 2010 · https://doi.org/10.1158/1055-9965.epi-10-0217

• Stage of adoption of the human papillomavirus vaccine among college women

  Preventive Medicine · 2008 · https://doi.org/10.1016/j.ypmed.2008.12.005

• Dose to Larynx Predicts for Swallowing Complications After Intensity-Modulated Radiotherapy

  International Journal of Radiation Oncology*Biology*Physics · 2008 · https://doi.org/10.1016/j.ijrobp.2008.02.048

Current projects

No projects listed.